EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Giuseppe Di Lorenzo, Antonio Verde, Luca Scafuri, Raffaele Baio, Francesco Grillone, Francesco Passaro, Felice Crocetto, Dario Bruzzese, Antonella Ferraioli, Eleonora Monteleone, Sabrina Rossetti, Vittorino Montanaro und 21 weitere

Oncology · 2025

DOI: 10.1159/000548317 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Oncology, 2025. Verfasst von Giuseppe Di Lorenzo und 32 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Quality of Life, Androgen Antagonists, Patient Reported Outcome Measures. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The burden of androgen deprivation therapy (ADT) is only partially captured by legacy prostate cancer questionnaires, which devote few items to hormonal sequelae. Patient-Reported Evaluation of the Effects of Hormone Therapy (PREVES-HOR) is a 29-item, distress-anchored instrument developed to quantify ADT-specific physical, emotional, cognitive, sexual, and body image morbidity from a patient-centered, subjective perspective. We report the prespecified phase 1 psychometric evaluation.

Methods

Italian-speaking men receiving ADT were consecutively enrolled. Participants completed PREVES-HOR plus external comparators for fatigue (REST), mood (HEAL-BDLC), sleep (PEACE), and well-being (WHO-5). Internal consistency was estimated with Cronbach’s α and McDonald’s ω; convergent validity with Spearman correlations; dimensionality with exploratory factor analysis (polychoric matrix, principal axis factoring, oblimin rotation, parallel analysis).

Results

One hundred and forty-five patients were analyzed. PREVES-HOR showed excellent reliability (α = 0.95; McDonald’s ω = 0.97; domain α/ω 0.80–0.95). Six factors – physical fatigue and pain, emotional well-being, mental clarity, quality of life, relationships and stress, sexual health and body image – accounted for 79% of variance, with a dominant general distress factor (∼50%). All but four items had communalities ≥0.40 and cross-loadings

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsQuality of LifeAndrogen AntagonistsPatient Reported Outcome MeasuresAntineoplastic Agents, HormonalHumansMaleAgedSurveys and QuestionnairesPsychometricsMiddle AgedReproducibility of ResultsAged, 80 and overFatigue

Stichwörter der Autor:innen

Androgen deprivation therapyPREVES-HOR questionnairePatient-reported outcomesProstate cancerQuality of life

Substanzen

Androgen AntagonistsAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy.
  • Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy.
  • UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
  • Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy, an.verde@aslsalerno.it.
  • Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy, an.verde@aslsalerno.it.
  • Department of Urology, Umberto I, Nocera Inferiore, Salerno, Italy.

Zitieren

APA

Di Lorenzo, G., Verde, A., Scafuri, L., Baio, R., Grillone, F., Passaro, F., Crocetto, F., Bruzzese, D., Ferraioli, A., Monteleone, E., Rossetti, S., Montanaro, V., Metta, G., Prata, F., Ruffo, A., Romeo, G., Balsamo, R., Calogero, A., Strianese, O., …, & Buonerba, C. (2025). Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy. Oncology. https://doi.org/10.1159/000548317

Vancouver

Di Lorenzo G, Verde A, Scafuri L, Baio R, Grillone F, Passaro F, et al. Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy. Oncology. 2025. doi:10.1159/000548317

BibTeX
@article{DiLorenzo2025,
  author = {Di Lorenzo, Giuseppe and Verde, Antonio and Scafuri, Luca and Baio, Raffaele and Grillone, Francesco and Passaro, Francesco and Crocetto, Felice and Bruzzese, Dario and Ferraioli, Antonella and Monteleone, Eleonora and Rossetti, Sabrina and Montanaro, Vittorino and Metta, Giacomo and Prata, Francesco and Ruffo, Antonio and Romeo, Giuseppe and Balsamo, Raffaele and Calogero, Armando and Strianese, Oriana and Maiorino, Francesco and Tartarone, Alfredo and Ferro, Matteo and Bove, Pierluigi and Donnarumma, Aniello and Verze, Paolo and Papalia, Rocco and Perdonà, Sisto and Riccio, Vittorio and Costa, Emma and Scocca, Concetta and Aliberti, Antonio and Cappuccio, Francesca and Buonerba, Carlo},
  title = {Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000548317}
}
Kostenlos starten →